No one particularly likes needles, including the person administering them and the person receiving medication with them—even in an emergency. So we are pleased to report efforts are being made to develop a dry powder nasal spray of epinephrine to treat anaphylaxis. The Food and Drug Administration (FDA) has already stated that nasal delivery can be an excellent alternative for delivery of rescue medications during life threatening patient events, such as drug overdoses.
News provided by
Jan 15, 2019
StellaPharma, Inc. (Stella) announced today that it has entered into an agreement whereby Stella will acquire the assets of G2B Pharma (G2B) including IP related to a dry powder nasal formulation of epinephrine being developed for anaphylaxis. Recent U.S. FDA product approvals indicate nasal delivery can be an excellent alternative route for delivery of rescue medications during life threatening patient events.